International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 08 August 2023

Page No: 1770-1781

DOI: https://doi.org/10.47191/ijmscrs/v3-i8-63, Impact Factor: 6.597

Reviewing and Exploring the Prospects of Platelet-Rich Plasma (PRP) Therapy in the Context of Pediatric Surgical Wound Management

Devina Subagio[1], Ahmad Fawzy[2]

[1]General practitioner, Kaliwiro Public Health Center, Wonosobo, Central Java, Indonesia

[2]Department of Plastic Surgery, Faculty of Medicine University of Jenderal Soedirman – Margono Soekarjo County Hospital, Indonesia

ABSTRACT

Pediatric surgical wound care is a critical aspect of medical practice, necessitating innovative approaches to optimize healing and minimize complications. Platelet-rich plasma (PRP) therapy has emerged as a promising intervention for enhancing wound healing in pediatric patients. This review comprehensively evaluates the efficacy, underlying mechanisms, and challenges associated with platelet-rich plasma (PRP) therapy in the context of pediatric surgical wounds.

Platelet-rich plasma (PRP), a biologic concentrate enriched with growth factors and cytokines, plays a pivotal role in wound healing by promoting cell proliferation, differentiation, and tissue regeneration. This article explores the mechanisms of action of this therapy in detail, focusing on its immunomodulatory effects and interaction with growth factors, and highlighting the significance of factors influencing platelet-rich plasma (PRP) efficacy, This article also gives examples of platelet-rich plasma (PRP) therapy in various pediatric surgical procedures, summarizes outcomes from clinical studies and trials, and addresses safety concerns and potential adverse effects associated with platelet-rich plasma (PRP) therapy in pediatric surgical wound management.

In conclusion, this review underscores the potential of platelet-rich plasma (PRP) therapy as an adjunctive treatment in pediatric surgical wound care. By elucidating its mechanisms, clinical efficacy, and challenges, the review provides insights for clinicians and researchers to guide evidence-based practice. Recommendations for future research and the integration of platelet-rich plasma (PRP) therapy into clinical guidelines emphasize the importance of refining protocols, ensuring cost-effectiveness, and adhering to ethical standards in pediatric surgical wound care.

KEYWORDS: pediatric surgical wound, platelet-rich plasma (PRP) therapy, wound healing, immunomodulatory effects

ARTICLE DETAILS

Published On:
31 August 2023

Available on:
https://ijmscr.org/

INTRODUCTION

The management of wounds in the pediatric population has garnered escalating concern among experts, propelled by the escalating intricacy of medical and surgical interventions tailored to this demographic. This complexity brings forth a grave risk of complications, encompassing recalcitrant surgical wounds, pressure-induced ulcers, and cutaneous impairment resulting from moisture.[1] Despite the universality of wound healing mechanisms—encompassing inflammation, proliferation, and maturation—certain divergences in pediatric skin physiology warrant meticulous attention during therapeutic interventions. Notably, the alteration of wound dressings tailored to pediatric proportions emerges as a salient task for pediatric wound care specialists, owing to the unavailability of suitably sized dressings.[1] Within the ambit of holistic pediatric wound care, alleviating pain stands as a pivotal objective.[3] The distinctive vulnerability of pediatric skin to epidermal stripping accentuates the risks inherent in adhesive wound dressing removal, as it is predisposed to epidermal tears and resultant tissue damage.[1,3]

The trajectory of platelet-rich plasma (PRP) has undergone a marked evolution since its inception in the 1970s, initiating within the hematology sphere.[4] Its subsequent integration into maxillofacial surgery, a decade later, can be attributed to its anti-inflammatory attributes fostering cellular proliferation.[5] This trajectory has further expanded to encompass diverse surgical domains, embracing cardiac, plastic, pediatric,

urological, gynecological, and orthopedic surgeries.[6] Grounded in this milieu, the present review aims to elucidate the multifaceted role of platelet-rich plasma (PRP) within pediatric surgical wound management. By unraveling its manifold implications, this inquiry strives to delineate the potential, prospects, and optimization avenues encapsulated within PRP's integration, thereby forging a comprehensive understanding of its therapeutic magnitude in the pediatric surgical paradigm.

Understanding platelet-rich plasma (PRP) therapy

Platelet-rich plasma (PRP), delineated as the plasma fraction derived from the patient's own blood, exhibiting an elevated platelet concentration exceeding baseline values,[7] encapsulates a rich milieu encompassing clotting factors, growth factors (GFs), chemokines, cytokines, and a diverse spectrum of proteins.[8,9] Its pivotal role in propelling wound healing is multifaceted, comprising the orchestration of inflammation modulation and the facilitation of angiogenesis and re-epithelialization processes.[10] Pertinently, platelet-rich plasma (PRP) orchestrates a pronounced reduction in the expression of inflammatory cytokines interleukin-17A (IL-17A) and interleukin-1β (IL-1β), fostering an environment conducive to effective wound healing by curbing unwarranted inflammation. Simultaneously, platelet-rich plasma (PRP) governs the trajectory of re-epithelialization through its modulation of the biological activity exhibited by epidermal stem cells (ESCs).[11] Beyond this, platelet-rich plasma (PRP) exhibits a remarkable ability to discharge antimicrobial compounds, thereby curtailing local inflammation and safeguarding wounds from potential infection.[12]

Foregoing the primacy of platelet concentration, the therapeutic efficacy of platelet-rich plasma (PRP) transcends a mere numerical threshold, engaging other pivotal components such as red blood cells, leukocytes, and an array of growth factors. Their intricate interplay is intricately shaped by the preparation technique employed for platelet-rich plasma (PRP) formulations, necessitating unequivocal elucidation within research endeavors.[13] This choreography of PRP's constituents is closely tied to factors influencing its yield, spanning blood draw methods, centrifugation dynamics encompassing speed, duration, temperature, and the usage of anticoagulants.[14] The prospect of PRP's efficacy pivots on an intricate symphony orchestrated by diverse variables, embracing the physiological profile of the patient, the methodologies governing platelet-rich plasma (PRP) preparation, and the techniques employed for its application. These variables, confluently intertwining patient-centric attributes and platelet-rich plasma (PRP) crafting nuances, span a spectrum encompassing age, gender, stature, dietary habits, blood pressure, mental and physical wellness, medication usage, and other lifestyle factors.[15] Particularly noteworthy, the platelet concentration embedded within platelet-rich plasma (PRP) formulations emerges as a pivotal determinant. Notably, the deployment of growth factors released through α-granule degranulation emerges as a pivotal determinant of PRP's therapeutic efficacy.[16] However, an assembly of reports raises the pertinent proposition that excessively elevating platelet concentrations does not confer proportional enhancements in regenerative properties, thereby suggesting an optimal concentration range spanning 2 to 10 times the baseline platelet count.[17,18] These discerning insights are buttressed by observations underpinning the potential for heightened growth factor concentrations and platelet levels to oversaturate the limited receptors for these factors, potentially culminating in exaggerated scar tissue formation and the inadvertent protraction of the healing process.[19,20]

Application of platelet-rich plasma (PRP) therapy in pediatric surgical wound care

Remarkable insights from a study involving 34 intricate pediatric surgical cases have unveiled a remarkable 68% success rate in wound healing, underscoring the profound potential of platelet-rich plasma (PRP) therapy.[21] This burgeoning interest in platelet-rich plasma (PRP) within wound repair stems from its capacity to expedite the proliferation of granulation tissue during the early stages of wound healing.[22,23] Its transformative impact is evidenced by the noteworthy shortening of wound healing timelines—PRP employment has effectively truncated the healing process from over 85 days to a mere 60 days compared to conventional approaches.[24] This augmentation extends to a significant enhancement in the complete and partial healing of difficult-to-heal wounds, outpacing the efficacy of routine wound care practices.[25,26]

Influence of platelet-rich plasma (PRP) extends across an array of pediatric surgical interventions, spanning cleft lip and palate repair, cardiac surgeries, and vacuum-assisted closure for gastroschisis.[27-32] In typical cleft lip procedures, platelet-rich plasma (PRP) assumes a pivotal role, with its administration into muscle and skin layers post-wound closure.[27] Furthering its applicability, platelet-rich plasma (PRP) appears to stimulate bone growth in alveolar clefts when coupled with autologous bone from the iliac crest during gingivoplasty procedures.[28] The trailblazing saga of platelet-rich plasma (PRP) continues within the realm of cardiac surgery, with applications spanning sternotomy-necessitated open cardiac surgeries, congenital heart disease procedures, and post-cardiopulmonary bypass scenarios.[29-31] In an illustrative instance, platelet-rich plasma (PRP) combined with vacuum-assisted closure (VAC) demonstrated significant efficacy in ameliorating gastroschisis-associated abdominal defects.[32] Notably, the prowess of platelet-rich plasma (PRP) therapy found affirmation in the management of congenital chyloperitoneum, manifesting its potential to curtail lymph leakage via intra-abdominal catheter

application.[33]

Pediatric burn injuries cast a somber shadow on global child healthcare, often necessitating complex surgical interventions due to the extensive wounds incurred.[34] In this arena, platelet-rich plasma (PRP) has emerged as a transformative entity, heralding a breakthrough in burn wound management.[35-38] Clinical investigations resoundingly highlight therapeutic efficacy of platelet-rich plasma (PRP) in augmenting wound healing while concurrently mitigating associated side effects.[35,36] The working mechanism of platelet-rich plasma (PRP) hinges on enhancing hemostasis, curbing blood loss; fostering the release of growth factors that expedite skin re-epithelialization and stimulate angiogenesis, thereby expediting healing; and wielding antimicrobial attributes that curtail infection risks.[35,39]

Under the scrutiny of a clinical trial in Egypt, the application of platelet-rich plasma (PRP) for second-degree facial burns via topical or intradermal routes emerged as a potent intervention, fostering improved healing outcomes albeit with certain complications.[40] Elucidating its potential within burn care, Gupta and colleagues unveiled heightened graft adherence rates through platelet-rich plasma (PRP) application, underscoring its beneficial influence over graft bed interactions.[41] Furthermore, platelet-rich plasma (PRP) significantly curtailed hematoma formation and resultant pain, validating its multifaceted impact.[41] Within this paradigm, Al Ibran and colleagues affirmed potential of platelet-rich plasma (PRP) therapy, even though it marginally extended wound healing timelines compared to standard dressing therapy, alluding to its complex influence on the healing cascade.[42] This complexity is further illuminated by findings that juxtaposed split-thickness skin grafting (STSG) with platelet-rich plasma (PRP), showcasing reduced scar recovery time and heightened tissue regeneration through accelerated re-epithelialization and angiogenesis.[43]

Synthesizing the cumulative evidence, recent investigations corroborate that integration of platelet-rich plasma (PRP) therapy into burn wound care distinctly expedites wound closure vis-à-vis conventional dressings, elevating it to a potentially pivotal therapeutic adjunct in burn victim management.[44]

Enhancing efficacy and ensuring safety in platelet-rich plasma (PRP) therapy for pediatric surgical wounds

The potential of autologous platelet-rich plasma (PRP) injections to augment the healing trajectory of cutaneous and muscle wounds while concurrently mitigating excessive scar formation is a noteworthy stride in pediatric wound care.[27] In an investigative effort by Gupta and colleagues, the influence of platelet-rich plasma (PRP) was scrutinized within cleft alveolus patients undergoing alveolar bone transplants. This study illuminated a distinct advantage for platelet-rich plasma (PRP) intervention, with Group A (PRP) displaying lesser pain and swelling compared to Group B (non-PRP), and a 6-month postoperative assessment revealing significantly elevated bone density within the PRP-augmented bone grafts.[28] These findings underline pivotal role of platelet-rich plasma (PRP) therapy in augmenting bone growth in alveolar clefts, synergizing with autologous bone grafts obtained from the iliac crest. Further corroborating this trend, an additional investigation delineated role of platelet-rich plasma (PRP) therapy as a safe and cost-effective repository of growth factors, fostering improved osteogenesis in alveolar bone grafting for cleft lip and palate patients. Notably, the study reported favorable regeneration ratios of bone to alveolar cleft within the PRP cases, reaffirming its potential in enhancing graft outcomes.[45] Encouragingly, these studies underscore the ease of platelet-rich plasma (PRP) extraction and its non-disruptive impact on the procedural workflow.

Expanding beyond surgical domains, efficacy of platelet-rich plasma (PRP) therapy extends to dermatological applications, particularly in addressing androgenetic alopecia (AGA). Platelet-rich plasma (PRP) therapy has emerged as an efficacious intervention to ameliorate hair loss concerns, as illustrated by qualitative assessments tracking stabilization and regrowth in response to platelet-rich plasma (PRP) therapy. Notably, the interventions were well-tolerated, reflecting favorable safety profile of platelet-rich plasma (PRP) therapy and minimal postoperative discomfort.[46]

Burn wound care represents another pivotal area where platelet-rich plasma (PRP) therapy exerts a transformative impact. Studies ascertain the acceleration of wound healing through platelet-rich plasma (PRP) administration, surpassing conventional dressing therapy timelines.[42] Platelet-rich plasma (PRP) interventions exhibit a dual potency, not only driving wound healing but also influencing scar tissue formation positively.[27] In the context of burn-induced neuropathic pain, therapeutic potential of platelet-rich plasma (PRP) therapy is exemplified by its ability to alleviate allodynia. Furthermore, insights gleaned from a rat model with burn injuries reveal that platelet-rich plasma (PRP) administration in the burn scar region is capable of reducing neuropathic pain, emphasizing its applicability in this challenging clinical scenario.[47]

However, it is paramount to tread cautiously, recognizing that alongside its promising benefits, platelet-rich plasma (PRP) usage harbors potential complications. The specter of infection or inadvertent damage to nerves or blood vessels looms, particularly contingent on the operator's expertise and the patient's underlying health status. For individuals with compromised immune systems or susceptibilities to specific illnesses, the risk of infection within the treated area escalates.[48] The nuances of interaction of platelet-rich plasma (PRP) with the immune system manifest through allergic responses, as evidenced by a case of eyelid puffiness, mucopurulent discharge, and skin rashes.[49]

Insights into the mechanisms of platelet-rich plasma (PRP) in pediatric wound healing

Platelet-rich plasma (PRP) emerges as a potent stimulator of cell proliferation, orchestrating its effects through the activation of an intricate network of growth factors and adhesion receptors. Notably, platelet-rich plasma (PRP) carries within it an arsenal of approximately 300 bioactive molecules, stored within platelet α-granules and dense granules, awaiting activation to drive the course of tissue regeneration.[50] Central to this process are growth factors (GFs) and cytokines, including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), transforming growth factor-β (TGF-β), among others, secreted by activated thrombocytes.[51] The influence of these growth factors transcends mere biochemical signaling, profoundly impacting cell division, migration, proliferation, and differentiation—cornerstones of the intricate choreography of wound healing. Their interaction with transmembrane receptors on target cells sets in motion a cascade of events that culminate in cell proliferation, migration, and the synthesis of the extracellular matrix (ECM), collectively shaping the landscape of tissue healing.[52] The profusion of these potent growth factors within platelet-rich plasma (PRP) renders it a compelling avenue for hastening wound healing processes.[53]



Figure 1. Contents in platelet-rich plasma (PRP) and platelet-rich plasma extracellular vehicles (PRP-EVs) and its role in regenerative medicine.[54]

While growth factors are pivotal in orchestrating the cellular dynamics of wound healing, their role extends beyond the cellular realm. These factors wield essential influence over inflammatory reactions, orchestrate the development of granulation tissue, and serve as catalysts for angiogenesis. Upon secretion, growth factors engage with specific membrane or cytoplasmic receptors, initiating a molecular symphony that enlists cellular machinery in the orchestration of wound healing.[55] Central to this symphony is the proliferation phase, marked by the emergence of granulation tissue and the inception of angiogenesis, crucial stages in the regenerative process.[56] Comprising fibroblasts, neovasculature, and macrophages interwoven within a collagen, hyaluronic acid (HA), and fibronectin matrix, granulation tissue stands as the scaffold that bridges wound gaps, ushering cell adhesion, migration, growth, and differentiation—a convergence critical to wound repair.[57] In tandem, macrophages in the inflammatory phase, ceaseless purveyors of growth factors, notably fibroblast growth factor (FGF), galvanize fibroblast activation and proliferation,

cementing their role as linchpins in granulation tissue formation.[58] The participation of fibroblasts, in response to the cues from platelet and macrophage-derived cytokines and growth factors, is pivotal in the construction of the granulation tissue scaffold—a living architectural marvel in the journey of wound healing.[56]

However, multifaceted influence of platelet-rich plasma (PRP) does not confine itself to proliferation and differentiation orchestration alone; it extends its sway into the anti-inflammatory and immunomodulatory mechanism.[59] The intriguing potential of platelet-rich plasma (PRP) to modulate the immune response is underscored by its reservoir of diverse cytokines, particularly the interplay with transforming growth factor-β1 (TGF-β1) in fostering the differentiation of T regulatory cells (Tregs).[59,60] Further attesting to its immunoregulatory prowess, PRP showcases a multifarious repertoire of immunomodulatory receptor molecules on its surface and within its cytoplasm. These encompass P-selectin, the transmembrane ligand CD40 (CD40L), cytokines such as interleukins IL-1β, IL-4, IL-10, IL-13, transforming growth factor-β (TGF-β), and platelet-specific toll-like receptors (TLRs), collectively endowing platelets with the capacity to engage in intricate interactions with an array of immune cells.[62,63] In effect, platelet-rich plasma (PRP) acts as a multifaceted communicator in the immune landscape, enriching our comprehension of its intricate roles beyond wound healing.[64]

Influential factors for the efficacy of platelet-rich plasma (PRP) in pediatric surgical wound care

The activation of platelets represents a pivotal phase that wields discernible impact on the availability of bioactive agents, thus intricately steering tissue repair processes.[65] The efficacy of platelet-rich plasma (PRP), in turn, is profoundly influenced by a spectrum of variables encompassing blood volume extracted, centrifugation velocity, duration, temperature, and the judicious choice of anticoagulants.[66-69] Noteworthy is the temporal aspect of blood acquisition, wherein larger-gauge needles (>22) are conventionally employed to forestall inadvertent platelet activation during the sampling process.[66] Intriguingly, the temperature environment during centrifugation emerges as a sentinel determinant, as highlighted by the American Association of Blood Banks (AABB) advocating a temperature range of 21°C-24°C for optimal PRP yield devoid of platelet activation.[67] Macey and colleagues underscore the significance of lower temperatures in assuaging platelet activation kinetics, thereby facilitating the procurement of PRP replete with functionally robust platelets.[68] The choice of anticoagulant proves pivotal, with the imperative of selecting agents that preserve the intrinsic potency, structural integrity, and configuration of platelets.[69] The consensus within the scholarly arena leans towards averting ethylenediaminetetraacetic acid (EDTA) due to its potential to undermine platelet membrane integrity. In this context, anticoagulants containing citrate and sodium citrate dextrose emerge as judicious choices.[69]



Figure 2. A method of isolation of platelet-derived products.[54]

While discernible strides have been made in understanding the tenets of platelet-rich plasma (PRP) utilization, the impact of age and gender on platelet and growth factor concentrations remains a salient area of investigation. Contrary to initial conjectures, extant research underscores a lack of significant fluctuations in platelet or growth factor

concentrations linked to age or gender, thereby negating the purported influence of these variables.[70] Nonetheless, it is essential to elucidate the relationship between hematocrit, total platelet count, and resultant PRP platelet concentration to bolster our comprehension of these dynamic interactions.

The optimal timeframe for platelet-rich plasma (PRP) administration emerges as a pivotal facet warranting elucidation, holding implications for judicious treatment. A notable experimental endeavor involving male white rabbits harboring nerve injuries elucidated that the temporal sweet spot for platelet-rich plasma (PRP) injection, conducive to nerve regeneration, materializes around 14 days post-injury.[71] This pinpointing of an ideal temporal window underscores the intricate interplay between platelet-rich plasma (PRP) administration and the dynamic stages of wound healing.

A vanguard study conducted by Elgarhy and colleagues stands testament to the versatile applicability of platelet-rich plasma (PRP), extending its therapeutic scope to encompass chronic venous leg ulcers. Comparing the efficacy and safety of platelet-rich plasma (PRP) injection with autologous topical platelet gel, the study discerned that both approaches efficaciously expedited the healing trajectory of these stubborn ulcers, unfurling affordable and safe alternatives in the clinical armamentarium.[72] This foray of platelet-rich plasma (PRP) into the arena of chronic wound management bespeaks its expansive therapeutic potential across varied wound types.

Advancing platelet-rich plasma (PRP) therapy in complex pediatric cases

Platelet-rich plasma (PRP) emerges as a potent therapeutic avenue, wielded with efficacy in managing wounds with diverse origins encompassing the gamut of acute, chronic, and postburn injuries. Of particular note is its role in attenuating the extended inflammatory phase inherent to chronic wounds, where its influence transcends conventional boundaries. Within this intricate milieu, growth factors ascend as key players, orchestrating the intricate symphony of cell migration, proliferation, and differentiation – essential constituents that converge toward the panorama of wound healing.[73]

Clinicians have acknowledged tole of platelet-rich plasma (PRP) in non-healing ulcers. The specter of non-healing ulcers materializes as a formidable public health quandary, reverberating across personal, professional, and societal strata.[74] In this backdrop, the advent of autologous platelet-rich plasma (PRP) therapy has heralded transformative strides, emboldened by its unassuming simplicity and cost-effective execution. Notably, this modality serves as a potent conduit for delivering the indispensable growth factors that steer the tissue healing cascade.[75] A seminal contribution by Suthar and colleagues presented an incisive case series encompassing twenty-four patients, each harboring lesions or ulcers rooted in diverse etiologies. Introducing a single dose of platelet-rich plasma (PRP) injections at the wound periphery coupled with topical application of autologous platelet gel, this intervention catalyzed the emergence of granulating tissue islands within a span of four weeks. These signs of healing were corroborated by noteworthy reductions in wound dimensions and commensurate elevations in tissue mass. This confluence of effects underscores the potential of platelet-rich plasma (PRP) therapy to potentially avert lower extremity amputations arising from intractable non-healing wounds.[75]

Diabetes Mellitus (DM) unveils itself as a chronic metabolic tapestry characterized by hyperglycemia – a hallmark signature propelled by disruptions in blood glucose dynamics.[76] Within the context of pediatric diabetes, the corridors of Type 1 Diabetes Mellitus (T1DM) harbor complex dynamics, engendering pancreatic insulin dearth due to autoimmune entanglements.[76] In this intricate interplay, vascular endothelial growth factor (VEGF) emerges as a powerful harbinger, sculpting angiogenic narratives imprinted within the landscape of diabetes-induced vascular anomalies.[77] In tandem, growth factors (GFs) constitute the fundamental orchestrators of cellular ballet, orchestrating the symphony of proliferation and differentiation that foments tissue rejuvenation. Remarkably, recent revelations disclose the potential of protracted administration of low-dose growth factors (GF) to engender the genesis of ductal cells and cell differentiation within the microcosm of diabetic murine models.[78] Central to this tapestry is the primordial role assumed by platelets, culminating in the wellspring of a panoply of growth factors. This intricate mosaic converges within the tenets of platelet-rich plasma (PRP), a therapeutic arsenal surging with autologous growth factor encomiums, superseding whole blood platelet levels by manifold.[79] A confluence of research epitomized by Zarin and colleagues casts light on intricate interplay of platelet-rich plasma (PRP) within the diabetic context, unraveling its potential to recalibrate plasma insulin and glucose dynamics while alleviating oxidative stress and fueling insulin production within pancreatic islets.[80] Further fortifying the corpus of knowledge, El-Tahawy and colleagues unfurled the transformative potential of platelet-rich plasma (PRP) interventions, heralding substantial reductions in hyperglycemia levels within experimental subjects.[81]

Hemophilia, standing as a preeminent bleeding disorder, imposes a compelling mandate for meticulous intervention since early childhood to avert grave complications.[82] A conspicuous manifestation within this milieu is hemophilic arthropathy, a vexing sequela culminating in chronic, irreversible joint impairments.[82] In a pioneering stride, Davoodabadi and colleagues conducted a clinical exploration, delving into the efficacy of platelet-rich plasma (PRP) as a therapeutic armamentarium to curtail pain and bolster physical functionality within hemophilic arthropathy

patients.[83] Their foray into the realms of clinical evaluation unveiled resounding echoes of success, discerned through statistically significant reductions in pain scores harnessed by the visual analog scale (Hemophilia Joint Health Score).[83]

Comparative analysis of platelet-rich plasma (PRP) in the spectrum of advanced pediatric wound therapies

Burn injuries, a prevalent affliction among the young, underscore a prominent public health concern as they stand as the fifth most prevalent form of non-fatal childhood injuries on a global scale. Remarkably, when contrasted with the adult demographic, children exhibit a heightened susceptibility to burns, necessitating a discerning lens on innovative therapeutic strategies.[34] The essence of burn injuries resides in their infliction of thermal trauma upon the integumentary fortress, precipitating a cascade of events that culminate in the impairment of the skin's quintessential protective mantle, a process intrinsically linked to the forfeiture of its barrier functions. This vulnerability foments a fertile ground for intricate sequelae, encompassing the specter of infection and the cloak of hypothermia, marshaling forth the impetus for pioneering interventions.[84]

As a modality in addressing the complex tapestry of burn injuries, skin grafting emerges as a pertinent recourse, especially in the context of profound second- or third-degree burns, where the impetus for primary or secondary wound healing finds its expression.[85] Within this labyrinthine framework, the exploration conducted by Al Ibran and colleagues assumes center stage, orchestrating a comparative inquiry into the efficacy of platelet-rich plasma (PRP) therapy vis-à-vis standard dressing regimens in the realm of partial-thickness burn wounds. Illuminatingly, their endeavors unveiled a trajectory wherein platelet-rich plasma (PRP) administration exerted a discernible influence on wound healing dynamics, with an accelerated temporal course witnessed in the platelet-rich plasma (PRP) cohort as opposed to the conventional dressing therapy group (18 days versus a minimum of 21 days; $p<0.05$). This perceptible acceleration crystallizes the prospect of employing platelet-rich plasma (PRP) as a conduit for expediting the healing journey, underscoring its potential to transcend traditional approaches.[42]

In further exploration of this paradigm, the amalgamation of split-thickness skin grafting (STSG) with platelet-rich plasma (PRP) surges forth as a prospective avenue, promulgating expedited tissue reinvigoration and scar maturation through the ennobled mechanisms of re-epithelialization and angiogenesis.[43] An intricate panorama gleaned from recent research underscores the unambiguous celerity embedded within platelet-rich plasma (PRP) applications, setting it apart as a promising therapeutic constituent in burn wound management. This salient insight holds the capacity to recalibrate the therapeutic trajectory, extending platelet-rich plasma (PRP) beyond its established confines and into the echelons of burn wound management.[44]

A meticulous meta-analysis by Li and colleagues casts a luminous gaze upon the comparative milieu between platelet-rich plasma (PRP) dressings and conventional saline dressings in the ambit of chronic wound management. The study's findings unravel a decisive verdict, as the platelet-rich plasma (PRP) dressing emerges as a harbinger of enhanced wound healing rates, signifying a statistically significant upsurge in complete healing compared to the conventional saline counterpart. This resounding pronouncement converges with an absence of statistical disparities in wound infection rates or untoward events, anchoring the narrative of platelet-rich plasma (PRP) as a potent therapeutic contender in the orchestration of wound healing trajectories.[86]

Challenges and limitations in pediatric platelet-rich plasma (PRP) therapy

The effectiveness of platelet-rich plasma (PRP) therapy hinges primarily upon the concentration of platelets, which inherently harbor the trove of growth factors indispensable for the orchestration of tissue regeneration. This cardinal attribute remains inextricably linked to the intricacies of the preparation methodology, serving as the bedrock upon which the therapeutic edifice is erected. Thus, in studies enlisting the prowess of platelet-rich plasma (PRP) therapy, meticulous delineation of both the preparation process and the ensuing platelet-rich plasma (PRP) composition emerges as an imperative, safeguarding the fidelity of therapeutic outcomes. Notably, the landscape of platelet production optimization has been woven with numerous stratagems, each illuminating the pathway towards the zenith of platelet yield.[13,14] The scholarly journey embarked upon by Dhurat and colleagues traversed a comprehensive appraisal of diverse platelet yield techniques, revealing a common thread manifesting in sequential steps encompassing blood collection, initial centrifugation for erythrocyte separation, successive centrifugation to concentrate platelets alongside allied components, and culminating in sample activation via platelet agonists.[14]

Venturing deeper into the realm of platelet-rich plasma (PRP) preparation, Muthu and colleagues unfurled an inventive tapestry, culminating in a platelet-rich plasma (PRP) generation protocol epitomizing maximal platelet abundance. The narrative of their endeavors unfolded within the meticulous orchestration of a sequence involving 10 millilters of blood, subject to an initial centrifugation at 100g for 15 minutes succeeded by a second centrifugation at 1600g for 20 minutes. Intriguingly, the crux of their methodology lay in the discerning choice of the lower one-third of the resultant product, a judicious decision that yielded resolute consistency in high platelet recovery rates (ranging from 86% to 99%) and concentration (amplified sixfold), all while preserving the sanctity of platelet integrity and viability.[87]

Inextricable from the discourse of therapeutic potential of

platelet-rich plasma (PRP) is its temporal application to the wounded landscape. Herein, the elucidations orchestrated by Pandunugrahadi and colleagues resonate as a harbinger of strategic precision. Their nuanced investigation postulated that the optimal juncture for initiating platelet-rich plasma (PRP) injections to expedite nerve regeneration is precisely 14 days following the inciting injury. This pivotal temporal nuance, intricately aligned with the sequence of Wallerian degeneration, underscores the discernment required in navigating the interplay of platelet-rich plasma (PRP) and tissue healing dynamics.[71] A congruent revelation emerges from the landscape of venous leg ulcer management, wherein the study conducted by Pandunugrahadi and colleagues paints a portrait of efficacious interventions, with both platelet-rich plasma (PRP) injection and topical gel regimens indelibly marked by their capacity to accelerate the restorative voyage of ulcers.[72]

A constellation of promise envelops platelet-rich plasma (PRP) therapy within the pantheon of wound healing and graft integration. Its methodology, distinguished by its efficacy, safety, and cost-effectiveness, renders it an alluring proposition that has resonated across diverse etiologies.[88,89] Noteworthy is the economic imperative that platelet-rich plasma (PRP) imparts, as it converges with reduced healthcare expenditures over an extended temporal expanse of five years while concurrently elevating the quality of life for individuals grappling with the ravages of diabetic ulcers. Within this framework, platelet-rich plasma (PRP) unfurls its mantle as an accessible modality poised to usher expedited healing trajectories.[90,91] Pervading the contours of orthopedic therapeutics, Landi and colleagues engage in a comparative exploration, spotlighting the cost-effectiveness delineated in terms of quality-adjusted life years. The resonance of their inquiry discerns platelet-rich plasma (PRP) therapy standing as the pivot, outlaying a financial premium for its heightened efficacy over conventional hyaluronic acid interventions within the milieu of moderate to severe knee osteoarthritis.[92]

In the kaleidoscope of burgeoning interest surrounding platelet-rich plasma (PRP) as a fulcrum for optimizing wound healing trajectories, ethical deliberations emerge as an inexorable corollary. Herein, the sanctity of patient-centered care unfurls, necessitating an elaborate and transparent elucidation of the procedure's intricacies. Such a discourse is manifestly characterized by comprehensive detailing encompassing the procedural nuances, the physician's rationale underpinning the valorization of platelet-rich plasma (PRP), the attendant risk spectrum, and the fiscal underpinnings of the therapeutic journey, cognizant of platelet-rich plasma (PRP)'s lack of insurance coverage.[93] These ethical considerations thereby underscore the multidimensional nature of platelet-rich plasma (PRP) therapy, emblematic of a landscape where scientific prowess intertwines with ethical consciousness in shaping the trajectory of pediatric wound care.

Future Perspectives and Recommendations

In the contemporary medical landscape, platelet-rich plasma (PRP) has witnessed a meteoric rise in prominence, encompassing diverse medical domains, among them pediatric surgery. The foundational underpinning lies in the pivotal role of platelets, steadfastly orchestrating the symphony of biological processes essential for optimal wound healing dynamics.[94] This ascent has been marked by an unprecedented surge in the clinical adoption of platelet-rich plasma (PRP) therapy, albeit amid a backdrop characterized by the conspicuous paucity of empirical validation underpinning its utility across myriad indications.[95] This juncture has served as a crucible for rigorous clinical scrutiny, evidenced by a confluence of trials that have sought to interrogate the therapeutic significance of platelet-derived modalities. Within this scientific terrain, rays of optimism have emerged, casting light upon a constellation of affirmative therapeutic outcomes, all while maintaining a vigil against the incursion of deleterious effects. It is noteworthy that these therapeutic achievements, often positioned within the realms of regenerative medicine, navigate amidst the undercurrent of discord regarding the blueprint for an optimal preparation technique, a narrative that continues to unfold within the realm of scientific discourse.[96]

Amidst the surging tide of deliberations, the domain of platelet-rich plasma (PRP) therapy stands resolute, fostering vibrant exploration across an eclectic spectrum of medical disciplines, encompassing dermatology, dentistry, ophthalmology, orthopedics, cardiology, plastic surgery, pediatrics, urology, and gynecology, among others.[6] This multifaceted canvas bespeaks the tangible promise that PRP-based interventions hold, aptly underscored by their economical tenor, effectively poised to supersede conventional therapeutic paradigms.[90-92,96] In the quest to steward a trajectory enriched by scientific and therapeutic enlightenment, the clarion call for orchestrated endeavors towards engendering consensus evidential streams cannot be understated. Within the ever-evolving crucible of clinical trials, it is incumbent to harness the collective insights gleaned from myriad investigations, thereby undergirding the architectural edifice for a standardized and efficacious formulation, culminating in definitive integration of platelet-rich plasma (PRP) as a therapeutic conduit primed for transformative wound healing exploits.

CONCLUSION

Platelet-rich plasma (PRP) holds significant potential as a method to enhance wound healing, a crucial process for overall organism health. Specifically, PRP plays a pivotal role in improving skin wound healing by orchestrating inflammation control, angiogenesis promotion, and re-

epithelialization acceleration. Across various pediatric surgical scenarios, numerous preclinical and clinical investigations have underscored the beneficial role of platelet-rich plasma (PRP). Processes like angiogenesis, macrophage activation, cell growth stimulation, and cellular proliferation have been implicated in the platelet-rich plasma (PRP) -driven enhancement of wound healing. Standardizing the preparation methodology is pivotal to achieve consistent and optimal outcomes with platelet-rich plasma (PRP) therapy. Despite its clinical use in wound healing, the safety of platelet-rich plasma (PRP)-based therapy in the context of pediatric immunological conditions warrants more comprehensive investigation.

Ethical and legal considerations stand out as crucial factors that necessitate careful attention when contemplating the implementation of PRP therapy. Further extensive research and clinical trials with larger sample sizes are essential to comprehensively evaluate PRP's utility as a regenerative therapeutic approach, particularly within the realm of pediatric surgery. Future research efforts should also focus on elucidating the optimal timing for PRP injections in relation to pediatric burn wound healing duration and hospital stay.

REFERENCES

I. King A, Stellar JJ, Blevins A, Shah KN. Dressings and products in pediatric wound care. Adv Wound Care. 2014; 3(4): 324–334.
II. Gonzalez AC, Costa TF, Andrade ZA, Medrado AR. Wound healing - A literature review. An Bras Dermatol. 2016; 91(5):614-620.
III. McCord SS, Levy ML. Practical guide to pediatric wound care. Semin Plast Surg. 20016; 20(3): 192-199.
IV. Andia I, Abate M. Platelet rich plasma: underlying biology and clinical correlates. Regen Med 2013; 8(5): 645-658.
V. Conde Montero E, Fernández Santos ME, Suárez Fernández R. Platelet-rich plasma: applications in dermatology. Actas Dermosifiliogr. 2015; 106(2): 104-111.
VI. Andia E, Rubio-Azpeitia J, Martin I, Abate M. Current concepts and translational uses of platelet rich plasma biotechnology; in Ekinci D (ed.): Biotechnology. InTech. 2015.
VII. Alves R, Grimald R. A review of platelet-rich plasma: History, biology, mechanism of action, and classification. Skin Appendage Disord. 2018; 4(1):18-24.
VIII. Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: a critical appraisal of the literature. J Dermatolog Treat 2016; 27(3): 285-289.
IX. Pavlovic V, Ciric M, Jovanovic V, Stojanovic P. Platelet rich plasma: a short overview of certain bioactive components. Open Med (Wars). 2016; 11(1): 242-247.
X. Xu P, Wu Y, Zhou L, Yang Z, Zhang X, Hu X, et al. Platelet-rich plasma accelerates skin wound healing by promoting re-epithelialization. Burns Trauma. 2020; 8:tkaa028.
XI. Lian Z, Yin X, Li H, Jia L, He X, Yan Y, et al. Synergistic effect of bone marrow-derived mesenchymal stem cells and platelet-rich plasma in streptozotocin-induced diabetic rats. Ann Dermatol. 2014; 26(1):1–10.
XII. Zhang W, Guo Y, Kuss M, Shi W, Aldrich AL, Untrauer J, et al. Platelet-rich plasma for the treatment of tissue infection: Preparation and clinical evaluation. Tissue Eng Part B Rev. 2019; 25(3):225-236.
XIII. Sharun K, Pawde AM. Variables affecting the potential efficacy of platelet-rich plasma in dermatology. J Am Acad Dermatol. 2021; 84(1): e47-e48.
XIV. Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: A review and author's perspective. J Cutan Aesthet Surg. 2014; 7(4):189-197.
XV. Kuffler DP. Variables affecting the potential efficacy of platelet-rich plasma (PRP) in providing chronic pain relief. J Pain Res. 2018; 12:109-116.
XVI. Collins T, Alexander D, Barkatali B. Platelet-rich plasma: a narrative review. 2021. EFORT Open Reviews, 6(4):225-235.
XVII. Verma R, Kandwal A, Negi G, Chandra H. Factors affecting the quantity and quality of platelet-rich plasma and platelet-derived growth factor-BB: an observational study. Journal of Bio-X Research. 2021; 4:67-70.
XVIII. Maisel-Campbell AL, Ismail A, Reynolds KA, et al. A systematic review of the safety and effectiveness of platelet-rich plasma (PRP) for skin aging. Arch Dermatol Res. 2020; 312:301-315.
XIX. Delong JM, Beitzel K, Mazzocca AD, et al. Update on platelet-rich plasma. Curr Orthop Pract. 2011; 22:514-523.
XX. Gamal AY, Abdel Ghaffar KA, Alghezwy OA. Crevicular fluid growth factors release profile following the use of platelet-rich fibrin and plasma rich growth factors in treating periodontal intrabony defects: a randomized clinical trial. J Periodontol. 2016; 87:654-662.
XXI. Mahmud SMK, Laizu J, Rashid A, Islam A, Mahmud SM. Platelet rich plasma (PRP) therapy in pediatric surgical wound care: My experience in a tertiary care hospital in Bangladesh. Sch J App Med Sci. 2023; 11(1):120-126.
XXII. Xia Y, Zhao J, Xie J, Lv Y, Cao DS. The Efficacy of platelet-rich plasma dressing for chronic non-

healing ulcers: A meta-analysis of 15 randomized controlled trials. Plast Reconstr Surg. 2019; 144(6):1463-1474.

XXIII. McAleer JP, Sharma S, Kaplan EM, Persich G. Use of autologous platelet concentrate in a nonhealing lower extremity wound. Adv Skin Wound Care. 2006; 19(7):354-363.

XXIV. Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta Dermatovenerol Alp Pannonica Adriat. 2007; 16(4):156-165.

XXV. O'Connell SM, Impeduglia T, Hessler K, Wang XJ, Carroll RJ, Dardik H. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen. 2008; 16(6):749-756.

XXVI. Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen. 2005; 13(6):531-536.

XXVII. Refahee SM, Aboulhassan MA, Abdel Aziz O, et al. Is platelet-rich plasma (PRP) effective in reducing the scar Width of primary cleft lip repair? A randomized controlled clinical study. Cleft Palate Craniofac J. 2020; 57(5):581-588.

XXVIII. Gupta C, Mehrotra D, Mohammad S, Khanna V, Singh GK, Singh G, et al. Alveolar bone graft with platelet rich plasma in cleft alveolus. J Oral Biol Craniofac Res. 2013; 3(1):3-8.

XXIX. Patel AN, Selzman CH, Kumpat GS, McKellar SH, Bull DA. Evaluation of autologous platelet rich plasma for cardiac surgery: outcome analysis of 2000 patients. J Cardiothorac Surg 11. 2016; 62.

XXX. Hiramatsu T, Okamura T, Imai Y, Kurosawa H, Aoki M, SHin'oka T, et al. Effects of autologous platelet concentrate reinfusion after open heart surgery in patients with congenital heart disease. Ann Thorac Surg. 2022; 73:1282-1285.

XXXI. Okamura T, Koh E, Yokoyama S. Effect of autologous platelet-rich plasma (PRP) in cardiac surgery. The Japanese Journal of Thoracic Surgery. 2001; 54(5): 397-400.

XXXII. Domenichelli V, Straziuso S, Sabatino M, Federici S. Vacuum assisted closure (VAC) and platelet-rich plasma (PRP): A successful combination in a challenging case of gastroschisis. Open Journal of Pediatrics. 2015; 5(3):274-278.

XXXIII. Joudi M, Alamdari DH, Rahimi HR. Successful treatment of congenital chyloperitoneum with platelet-rich fibrin glue. Iran J Pediatr. 2013; 23(3):357-359.

XXXIV. Jordan KC, Di Gennaro JL, von Saint André-von Arnim A, Stewart BT. Global trends in pediatric burn injuries and care capacity from the World Health Organization Global Burn Registry. Front Pediatr. 2022; 10:954995.

XXXV. Huang H, Sun X, Zhao Y. Platelet-rich plasma for the treatment of burn wounds: A meta-analysis of randomized controlled trials. Transfus Apher Sci. 2021; 60(1):102964.

XXXVI. Chen Z, Wu Y, Turxun N, Shen Y, Zhang X. Efficacy and safety of platelet-rich plasma in the treatment of severe burns: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(45):e23001.

XXXVII. Kao YC, Lin DZ, Lee SL, Chen C, Wang HJ, Chiu WK. Assisted therapy with platelet-rich plasma for burn patients: A meta-analysis and systematic review. Burns. 2021; 47(5):1012-1023.

XXXVIII. Pradnyandari NKPD, Natasha RR. The role of Platelet-Rich Plasma (PRP) in burn wound healing: a literature-review. Intisari Sains Medis. 2022; 13(2):507-510.

XXXIX. Jain NK, Gulati M. Platelet-rich plasma: a healing virtuoso. Blood Res. 2016; 51(1):3-5.

XL. Elsayed AB, Moiemen NS, Eloteify MM, Mousa AK. Applied effectiveness of platelet rich plasma on partial thickness facial burn healing in comparison to conventional facial burn care. Aswan University Med Journal. 2022; 2(2); 25-33.

XLI. Gupta S, Goil P, Thakurani S. Autologous platelet rich plasma as a preparative for resurfacing burn wounds with split thickness skin grafts. World J Plast Surg. 2020; 9(1):29-32.

XLII. Al Ibran E, Rao MH, Khan M, Hasan F. Efficacy of platelet rich plasma application in comparison to conventional dressing therapy in partial thickness burn wound. Medical Forum Monthly. 2014; 25(1):27-30.

XLIII. Klosová H, Stětinský J, Bryjová I, Hledík S, Klein L. Objective evaluation of the effect of autologous platelet concentrate on post-operative scarring in deep burns. Burns. 2013; 39(6):1263-1276.

XLIV. Kao YC, Lin DZ, Lee SL, Chen C, Wang HJ, Chiu WK. Assisted therapy with platelet-rich plasma for burn patients: A meta-analysis and systematic review. Burns. 2021; 47(5):1012-1023.

XLV. Oyama T, Nishimoto S, Tsugawa T, Shimizu F. Efficacy of platelet-rich plasma in alveolar bone grafting. J Oral Maxillofac Surg. 2004; 62(5):555-558.

XLVI. Tawfik C, Tejeda CI, Haughton AM. Case series evaluating the efficacy and safety of platelet-rich plasma for androgenetic alopecia in pediatric patients. JAAD Case Rep. 2023; 37:8-12.

XLVII. Huang SH, Wu SH, Lee SS, et al. Platelet-rich plasma injection in burn scar areas alleviates

neuropathic scar pain. Int J Med Sci. 2018; 15(3):238-247.

XLVIII. Medina-porqueres I, Moreno-pedrosa C, Mateo-rodrıguez J, Rosado-velazquez D. An early-exercise-mediated adverse reaction associated with platelet-rich plasma therapy. Turk J Physiother Rehabil. 2022; 33(1):85-89.

XLIX. Latalski M, Walczyk A, Fatyga M, et al. Allergic reaction to platelet-rich plasma (PRP): Case report. Medicine (Baltimore). 2019; 98(10):e14702.

L. Puricelli C, Boggio E, Gigliotti CL, et al. Platelets, protean cells with all-around functions and multifaceted pharmacological applications. Int J Mol Sci. 2023; 24(5):4565.

LI. Cecerska-Heryć E, Goszka M, Serwin N, Roszak M, Grygorcewicz B, Heryć R, Dołęgowska B. Applications of the regenerative capacity of platelets in modern medicine. Cytokine Growth Factor Rev. 2022; 64:84-94.

LII. Gentile P, Garcovich S. Systematic review-the potential implications of different platelet-rich plasma (PRP) concentrations in regenerative medicine for tissue repair. Int J Mol Sci. 2020; 21(16):5702.

LIII. Misiura M, Guszczyn T, Oscilowska I, Baszanowska W, Palka J, Miltyk W. Platelet-rich plasma promotes the proliferation of human keratinocytes via a progression of the cell cycle. A role of prolidase. Int J Mol Sci. 2021; 22(2):936.

LIV. Wu J, Piao Y, Liu Q, Yang X. Platelet-rich plasma-derived extracellular vesicles: A superior alternative in regenerative medicine? Cell Prolif. 2021 Dec;54(12):e13123.

LV. Yamakawa S, Hayashida K. Advances in surgical applications of growth factors for wound healing. Burns Trauma. 2019; 7:10.

LVI. Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci. 2016; 73(20):3861-3885.

LVII. Diller RB, Tabor AJ. The role of the extracellular matrix (ECM) in wound healing: A Review. Biomimetics (Basel). 2022; 7(3):87.

LVIII. Park JW, Hwang SR, Yoon IS. Advanced growth factor delivery systems in wound management and skin regeneration. Molecules. 2017; 22(8):1259.

LIX. Kauhl W, Pototschnig H, Paasch U. Can platelet-rich plasma reduce the burden of inflammatory skin diseases such as psoriasis and atopic dermatitis? Cureus. 2021; 13(10):e18472.

LX. Huber SC, de Lima Montalvão SA, Sachetto Z, Santos Duarte Lana JF, Annichino-Bizzacchi JM. Characterization of autologous platelet rich plasma (PRP) and its biological effects in patients with Behçet's disease. Regen Ther. 2021; 18:339-346.

LXI. Durán G, Luzo AMC, Favaro WJ, Durán N. Nanostructured platelet-rich plasma: state of art in dental treatments. Braz Dent Sci. 2020; 23(2):1-10.

LXII. Cognasse F, Laradi S, Berthelot P, Bourlet T, Marotte H, Mismetti P, Garraud O, Hamzeh-Cognasse H. Platelet inflammatory response to stress. Front Immunol. 2019; 10:1478.

LXIII. Tejapira K, Yongpisarn T, Sakpuwadol N, Suchonwanit P. Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review. Front Med (Lausanne). 2022; 9:1058431.

LXIV. de Castro Roston JR, Reis IB, Luzo ÂCM, Roston MO, Durán N, Fávaro WJ. Evaluation of the tissue repair process and immunomodulatory action of platelet-rich plasma (PRP) in the treatment of abdominal stretch marks. Tissue Cell. 2023; 83:102132.

LXV. Cavallo C, Roffi A, Grigolo B, Mariani E, Pratelli L, Merli G, Kon E, Marcacci M, Filardo G. Platelet-Rich Plasma: The choice of activation method affects the release of bioactive molecules. Biomed Res Int. 2016; 2016:6591717.

LXVI. Marlovits S, Mousavi M, Gäbler C, Erdös J, Vécsei V. A new simplified technique for producing platelet-rich plasma: a short technical note. Eur Spine J. 2004; 13 Suppl 1(Suppl 1): S102-6.

LXVII. Sweeny J, Grossman BJ. Blood collection, storage and component preparation methods. In: Brecher M, editor. Technical Manual. 14th ed. Bethesda MD: American Association of Blood Banks (AABB); 2002. pp. 955–8.

LXVIII. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, et al. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem. 2002; 48:891–9.

LXIX. Anitua E, Prado R, Sánchez M, Orive G. Platelet-rich-plasma: Preparation and formulation. Oper Tech Orthop. 2012; 22:25–32.

LXX. Woodell-May JE, Ridderman DN, Swift MJ, Higgins J. Producing accurate platelet counts for platelet rich plasma: Validation of a hematology analyzer and preparation techniques for counting. J Craniofac Surg. 2005; 16:749–59.

LXXI. Pandunugrahadi M, Irianto KA, Sindrawati O. The optimal timing of platelet-rich plasma (PRP) injection for nerve lesion recovery: A preliminary study. Int J Biomater. 2022; 2022:9601547.

LXXII. Elgarhy LH, El-Ashmawy AA, Bedeer AE, Al-Bahnasy AM. Evaluation of safety and efficacy of autologous topical platelet gel vs platelet rich

plasma injection in the treatment of venous leg ulcers: A randomized case control study. Dermatol Ther. 2020; 33(6): e13897.

LXXIII. Conde-Montero E, Horcajada-Reales C, Clavo P, Delgado-Sillero I, Suárez-Fernández R. Neuropathic ulcers in leprosy treated with intralesional platelet-rich plasma. Int Wound J. 2016; 13:726–728.

LXXIV. Sebastian KMS, Lobato I, Hernandez I, et al. Efficacy and safety of autologous platelet rich plasma for the treatment of vascular ulcers in primary care: phase III study. BMC Fam Pract. 2014; 15:211.

LXXV. Suthar M, Gupta S, Bukhari S, Ponemone V. Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series. J Biomed Sci. 2017; 4(1):16.

LXXVI. American Diabetes Association. Diagnosis and classification of diabetes mellitus [published correction appears in Diabetes Care. Diabetes Care. 2010; 33 Suppl 1(Suppl 1):S62-S69.

LXXVII. Shi GJ, Shi GR, Zhou JY, Zhang WJ, Gao CY, Jiang YP, et al. Involvement of growth factors in diabetes mellitus and its complications: A general review. Biomed Pharmacother. 2018; 101:510-527.

LXXVIII. Zhang M, Lin Q, Qi T, Wang T, Chen CC, Riggs AD, et al. Growth factors and medium hyperglycemia induce Sox9+ ductal cell differentiation into β cells in mice with reversal of diabetes. Proc Natl Acad Sci U S A. 2016 Jan; 113(3):650-5.

LXXIX. Lister INE, Wienaldi. Antidiabetic effects of the Platelet Rich Plasma (PRP): A Review. Int J Res Pharm Sci. 2022; 13(3):292-296.

LXXX. Zarin M, Karbalaei N, Keshtgar S, Nemati M. Platelet-rich plasma improves impaired glucose hemostasis, disrupted insulin secretion, and pancreatic oxidative stress in streptozotocin-induced diabetic rat. Growth Factors. 2019; 37(5-6):226-237.

LXXXI. El-Tahawy NF, Rifaai RA, Saber EA, Saied SR, Ibrahim RA. Effect of platelet rich plasma (PRP) injection on the endocrine pancreas of the experimentally induced diabetes in male albino rats: A histological and immunohistochemical study. J Diabetes Metab. 2017; 8(3).

LXXXII. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost. 2021; 19(9):2112-2121.

LXXXIII. Davoodabadi H, Malek F, Habibpanah B, Ghoojani A. The efficacy of platelet-rich plasma in the treatment of hemophilic arthropathy. J Res Orthop Sci. 2020; 7(4):165-168.

LXXXIV. Suman A, Owen J. Update on the management of burns in paediatrics. BJA Educ. 2020; 20(3):103-110.

LXXXV. Anyanwu JA, Cindass R. Burn Debridement, Grafting, and Reconstruction. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.

LXXXVI. Li S, Xing F, Yan T, Zhang S, Chen F. The efficiency and safety of platelet-rich plasma dressing in the treatment of chronic wounds: A systematic review and meta-analysis of randomized controlled trials. J Pers Med. 2023; 13(3):430.

LXXXVII. Muthu S, Krishnan A, Ramanathan KR. Standardization and validation of a conventional high yield platelet-rich plasma preparation protocol. Ann Med Surg (Lond). 2022; 82:104593.

LXXXVIII. Oliveira BGRB, Carvalho MR, Ribeiro APL. Cost and effectiveness of Platelet Rich Plasma in the healing of varicose ulcer: Meta-analysis. Rev Bras Enferm. 2020; 73(4):e20180981.

LXXXIX. Sarvajnamurthy S, Suryanarayan S, Budamakuntala L, Suresh DH. Autologous platelet rich plasma in chronic venous ulcers: study of 17 cases. J Cutan Aesthet Surg. 2013; 6(2):97-9.

XC. Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care. 2008; 21(12):568-75.

XCI. Cobos R1, Aizpuru F, Parraza N, Anitua E, Orive G. Effectiveness and efficiency of platelet rich plasma in the treatment of diabetic ulcers. Curr Pharm Biotechnol. 2015; 16(7):630-4,

XCII. Landi S, Landa P, Russo S. Knee OA management: A cost effectiveness analysis of platelet-rich plasma versus hyaluronic acid for the intra-articular treatment of knee OA in France. Int J Clin Rheumatol. 2018; 13(5):307-318.

XCIII. Codorean IB, Cernat E, Popescu D, Sinescu RD, Perlea P. Legal and ethical aspects of Platelet-Rich Plasma. Rom J Leg Med. 2017; 25(4):405-408.

XCIV. White C, Brahs A, Dorton D, Witfill K. Platelet-Rich Plasma: A comprehensive review of emerging applications in medical and aesthetic dermatology. J Clin Aesthet Dermatol. 2021; 14(11):44-57.

XCV. Nazaroff J, Oyadomari S, Brown N, Wang D. Reporting in clinical studies on platelet-rich plasma therapy among all medical specialties: A systematic review of Level I and II studies. PLoS One. 2021; 16(4): e0250007.

XCVI. Verma R, Kumar S, Garg P, Verma YK. Platelet-rich plasma: a comparative and economical therapy for wound healing and tissue regeneration. Cell Tissue Bank. 2023; 24:285–306.